{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:05:38Z","timestamp":1791198338276,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Periodontitis is a chronic inflammatory disease characterized by gingival inflammation, alveolar bone resorption, and periodontal tissue destruction. Complement activation, particularly through the C3 component, plays a critical role in the inflammatory processes underlying periodontitis. AMY-101, a selective inhibitor of complement C3, has demonstrated significant potential in modulating complement activity and mitigating periodontal inflammation. This study comprehensively evaluates AMY-101\u2019s effects through <jats:italic>in vitro<\/jats:italic>, preclinical, and clinical studies. Mechanistic investigations revealed that AMY-101 effectively suppresses pro-inflammatory cytokines and matrix metalloproteinases (MMPs), reducing tissue destruction. Preclinical models confirmed AMY-101\u2019s ability to improve clinical parameters such as probing pocket depth, attachment loss, and bone preservation. Moreover, clinical trials demonstrated AMY-101\u2019s safety and efficacy in reducing gingival inflammation and bleeding without serious adverse events. These findings highlight AMY-101\u2019s therapeutic potential for periodontitis and broader applicability in other complement-driven inflammatory diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1587126","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:10:51Z","timestamp":1745899851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["AMY-101 as complement C3 inhibitor for periodontitis therapy: mechanisms, efficacy, and clinical translation"],"prefix":"10.3389","volume":"16","author":[{"given":"Jialun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne Nishio","family":"Ayre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/idj.12630","article-title":"Current concepts in the management of periodontitis","volume":"71","author":"Kwon","year":"2021","journal-title":"Int Dent J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/prd.2017.75.issue-1","article-title":"Periodontitis: facts, fallacies and the future","volume":"75","author":"Slots","year":"2017","journal-title":"Periodontol 2000"},{"key":"B3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nri3785","article-title":"Periodontitis: from microbial immune subversion to systemic inflammation","volume":"15","author":"Hajishengallis","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0293118","DOI":"10.1371\/journal.pone.0293118","article-title":"Overview of oral health status and associated risk factors in maritime settings: An updated systematic review","volume":"18","author":"Nguyen","year":"2023","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/JPER.21-0530","article-title":"Complement component 3 and its activation split-products in saliva associate with periodontitis","volume":"93","author":"Damgaard","year":"2022","journal-title":"J Periodontol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00406","article-title":"Complement-dependent mechanisms and interventions in periodontal disease","volume":"10","author":"Hajishengallis","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4103\/jispcd.JISPCD_161_22","article-title":"C3 targeted complement therapy for chronic periodontitis - A scoping review","volume":"12","author":"Agnihotri","year":"2022","journal-title":"J Int Soc Prev Community Dent"},{"key":"B8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.clim.2018.09.004","article-title":"Safety profile after prolonged C3 inhibition","volume":"197","author":"Reis","year":"2018","journal-title":"Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2019.07.006","article-title":"Analysis of the complement system in the clinical immunology laboratory","volume":"39","author":"Ling","year":"2019","journal-title":"Clin Lab Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00704-1","article-title":"Complosome - the intracellular complement system","volume":"19","author":"West","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2024.45.240050","article-title":"Immunodeficiency: complement disorders","volume":"45","author":"McMurray","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"104520","DOI":"10.1016\/j.dci.2022.104520","article-title":"An overview of complement systems in teleosts","volume":"137","author":"Li","year":"2022","journal-title":"Dev Comp Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/pharmrev.120.000072","article-title":"Therapeutic targeting of the complement system: from rare diseases to pandemics","volume":"73","author":"Garred","year":"2021","journal-title":"Pharmacol Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12974-020-02033-7","article-title":"Macrophage to myofibroblast transition contributes to subretinal fibrosis secondary to neovascular age-related macular degeneration","volume":"17","author":"Little","year":"2020","journal-title":"J Neuroinflammation"},{"key":"B15","article-title":"The human C3b receptor (CR1)","volume":"18","author":"Weiss","year":"1989","journal-title":"Adv Nephrol Necker Hosp"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.04.022","article-title":"Inhibition of C5AR1 impairs osteoclast mobilization and prevents bone loss","volume":"31","author":"Pimenta-Lopes","year":"2023","journal-title":"Mol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1403068","article-title":"Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth","volume":"194","author":"Coulthard","year":"2015","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41598-022-27279-4","article-title":"Purified complement C3b triggers phagocytosis and activation of human neutrophils via complement receptor 1","volume":"13","author":"Boero","year":"2023","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2187","article-title":"Osteoclast-derived complement component 3a stimulates osteoblast differentiation","volume":"29","author":"Matsuoka","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)37046-2","article-title":"Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis","volume":"267","author":"Wingrove","year":"1992","journal-title":"J Biol Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200338","article-title":"Complement is required for microbe-driven induction of Th17 and periodontitis","volume":"209","author":"Wang","year":"2022","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/JPER.23-0692","article-title":"Inflammation and tissue remodeling mediator expression during gingivitis: A comparison between experimental, naturally occurring gingivitis, and periodontal health","volume":"95","author":"Hsu","year":"2024","journal-title":"J Periodontol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00683","article-title":"Potential bidirectional relationship between periodontitis and alzheimer\u2019s disease","volume":"11","author":"Liccardo","year":"2020","journal-title":"Front Physiol"},{"key":"B24","first-page":"33","article-title":"Complement components and receptors: deficiencies and disease associations","volume":"52","author":"Bartholomew","year":"1990","journal-title":"Immunol Ser"},{"key":"B25","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3390\/pathogens11090983","article-title":"Increased levels of C5a in gingival crevicular fluid and saliva of patients with periodontal disease","volume":"11","author":"Bhalla","year":"2022","journal-title":"Pathogens"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201703-0660OC","article-title":"Blockade of the complement C5a\/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects","volume":"197","author":"Ajona","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2023.01.011","article-title":"Stiffness-tuned and ROS-sensitive hydrogel incorporating complement C5a receptor antagonist modulates antibacterial activity of macrophages for periodontitis treatment","volume":"25","author":"Gan","year":"2023","journal-title":"Bioact Mater"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202339","article-title":"Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist","volume":"189","author":"Abe","year":"2012","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2016.03.006","article-title":"Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application","volume":"28","author":"Hajishengallis","year":"2016","journal-title":"Semin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-020-03621-w","article-title":"Complement activation links inflammation to dental tissue regeneration","volume":"24","author":"Bergmann","year":"2020","journal-title":"Clin  Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/jcpe.13189","article-title":"Periodontitis and cardiovascular diseases: Consensus report","volume":"47","author":"Sanz","year":"2020","journal-title":"J Clin Periodontol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.3390\/ijms20184541","article-title":"Linkage of periodontitis and rheumatoid arthritis: current evidence and potential biological interactions","volume":"20","author":"de Molon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.07.017","article-title":"Inhibition of complement C3 signaling ameliorates locomotor and visual dysfunction in autoimmune inflammatory diseases","volume":"31","author":"Xu","year":"2023","journal-title":"Mol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/eci.2015.45.issue-4","article-title":"Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention","volume":"45","author":"Mastellos","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/omi.2016.31.issue-1","article-title":"Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention","volume":"31","author":"Mastellos","year":"2016","journal-title":"Mol  Microbiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.08.001","article-title":"Safety and efficacy of the complement inhibitor AMY-101 in a natural model of periodontitis in non-human primates","volume":"6","author":"Kajikawa","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.1038\/s41467-021-25745-7","article-title":"C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates","volume":"12","author":"Schmitz","year":"2021","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"108450","DOI":"10.1016\/j.clim.2020.108450","article-title":"The first case of COVID-19 treated with the complement C3 inhibitor AMY-101","volume":"215","author":"Mastaglio","year":"2020","journal-title":"Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244307","article-title":"Acadesine suppresses TNF-\u03b1 induced complement component 3 (C3), in retinal pigment epithelial (RPE) cells","volume":"15","author":"Efstathiou","year":"2020","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.298984","article-title":"Diversity in the C3b [corrected] contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family","volume":"287","author":"Garcia","year":"2012","journal-title":"J Biol Chem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/SHK.0000000000001127","article-title":"Protective effects of the complement inhibitor compstatin CP40 in hemorrhagic shock","volume":"51","author":"van Griensven","year":"2019","journal-title":"Shock"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.8b00263","article-title":"Gingival exudatome dynamics implicate inhibition of the alternative complement pathway in the protective action of the C3 inhibitor Cp40 in nonhuman primate periodontitis","volume":"17","author":"Bostanci","year":"2018","journal-title":"J Proteome Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000465455","article-title":"IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro","volume":"41","author":"Wu","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300242","article-title":"The Complement-Targeted Inhibitor Mini-FH Protects against Experimental Periodontitis via Both C3-Dependent and C3-Independent Mechanisms","volume":"211","author":"Li","year":"2023","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"101608","DOI":"10.1016\/j.smim.2022.101608","article-title":"C3-targeted host-modulation approaches to oral inflammatory conditions","volume":"59","author":"Kajikawa","year":"2022","journal-title":"Semin Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S136453","article-title":"Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model","volume":"12","author":"Wolf-Grosse","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/jcpe.2016.43.issue-3","article-title":"Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3","volume":"43","author":"Maekawa","year":"2016","journal-title":"J Clin Periodontol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1590\/1807-3107bor-2020.vol34.0026","article-title":"Periodontal disease and its impact on general health in Latin America. Section V: Treatment of periodontitis","volume":"34","author":"Fischer","year":"2020","journal-title":"Braz  Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.clim.2020.108391","article-title":"Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates","volume":"214","author":"Hughes","year":"2020","journal-title":"Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00488-6","article-title":"Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities","volume":"21","author":"Hajishengallis","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152973","article-title":"Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation","volume":"131","author":"Hasturk","year":"2021","journal-title":"J Clin Invest"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1078891","article-title":"Impact of neutrophil extracellular traps on fluid properties, blood flow and complement activation","volume":"13","author":"Burmeister","year":"2022","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400569","article-title":"Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis","volume":"192","author":"Maekawa","year":"2014","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2016.06.013","article-title":"From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage","volume":"221","author":"Mastellos","year":"2016","journal-title":"Immunobiology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"17038","DOI":"10.1038\/nrdp.2017.38","article-title":"Periodontal diseases","volume":"3","author":"Kinane","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.08.001","article-title":"C3-targeted therapy in periodontal disease: moving closer to the clinic","volume":"42","author":"Hajishengallis","year":"2021","journal-title":"Trends Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1587126\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:10:53Z","timestamp":1745899853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1587126\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2025.1587126"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1587126","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"article-number":"1587126"}}